Ingrown toenail monograph
This article was originally published in The Tan Sheet
Executive Summary
Sodium sulfide 1% gel is safe, effective for OTC use in treating pain and discomfort associated with ingrown toenails, according to final rule published in 1May 7 Federal Register. Rule creates a new monograph for OTC ingrown toenail relief products in which sodium sulfide 1% is the first ingredient. FDA stipulates gel be used with a retainer ring system to keep product at the area of application, as suggested in the agency's October 2002 proposed rule (2"The Tan Sheet" Oct. 7, 2002, p. 14). Schering-Plough submitted data on the safety of the retainer ring in October 1998; the firm has said in the past it plans to market a sodium sulfide product under its Dr. Scholl's foot care brand. Schering may introduce a product within 30 days of the final rule's publication...
You may also be interested in...
Ingrown Toenail Treatment Use With Retainer Ring System Proposed By FDA
Sodium sulfide 1% gel is safe and effective for OTC treatment of ingrown toenail pain only when used with a retainer ring system to keep the product at the area of application, FDA says in a 1proposed rule published in the Federal Register Oct. 4
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.